96 results about "Herpes zoster virus" patented technology

A method for using thiazine dyes, especially methylene blue or methylene blue derivatives, in an immediate or controlled release formulation, alone or in combination with low levels of light or other drugs, to selectively inactivate or inhibit hepatitis infection, has been developed. Clinical trial results demonstrate efficacy in a human clinical trial for treatment of hepatitis C by oral administration of methylene blue immediate release formulation, in a dosage of 65 mg twice daily, over a period of at least 100 days. A method for using thiazine dyes, especially methylene blue or methylene blue derivatives, in an immediate or controlled release formulation, along or in combination with low levels of light or other drugs, to prevent or decrease reactivation of viruses, is also described. The preferred class of patient is infected with, or has been exposed to, viruses such as Herpes simplex virus type 1 & 2, Varicella zoster virus, Epstein-Barr virus, Cytomegalovirus, and Herpes virus type 6 & 7, Adenovirus, and Human polyoma viruses, e.g. JC virus and BK virus. In one embodiment the thiazine dye is administered to a patient experiencing symptoms or disease caused by reactivation of a virus. In a preferred embodiment the thiazine dye is administered to a patient at risk for or experiencing symptoms or disease caused by reactivation of a virus, prior to or during immunosuppression or chemotherapy.

The invention relates to a neutralizing epitope peptide (or a variant thereof) from varicella-zoster virus virus (VZV) gE protein, a recombinant protein containing the neutralizing epitope peptide (or the variant thereof) and a carrier protein, and applications of the neutralizing epitope peptide (or a variant thereof) and the recombinant protein, and also relates to an antibody aiming to the neutralizing epitope peptide, a cell strain producing the antibody, and the applications thereof, and also relates to a vaccine containing the neutralizing epitope peptide and the recombinant protein, a medicine composition including the antibody, and the applications thereof, e.g., the application for preventing and/or treating VZV infection or one or more diseases and symptoms related to the infection.

Jojoba alcohol, a mixture of long chain monounsaturated alcohols, is an oily liquid at moderate ambient temperatures. It is readily absorbed by human skin where it relieves irritation and inhibits the formation of lesions caused by viruses. The inhibitory action is applicable to enveloped viruses which express as sores at dermal surfaces in humans. When applied topically to an incipent herpes episode, it will quickly penetrate the epidermis to the subdermal vascular cells and suppress viral replication which leads to inflammation and the formation of blisters on the face, genital and other skin and mucosal areas. Fumaric acid and malonic acid at low concentrations also inhibit the replication of varicella zoster virus in human cell cultures, with no cellular toxicity. Compositions of certain low molecular weight organic acids in jojoba alcohol enhance antiviral activity. Topical treatment of shingles with a low concentration of fumaric acid in jojoba alcohol terminates the episode. This combination drug acts by a dual mechanism wherein the jojoba alcohol blocks viral fusion by a lipoidal mode, and the polycarboxylic acids inhibit viral fusion by an ionic mode. The combination drug can also be effective in treating chicken pox. Jojoba alcohol is a carrier and transdermal delivery system for these and other pharmacologically active agents for the relief of pain and treatment of other conditions which occur at or under the surface of the skin. Topically applied jojoba alcohol is non-toxic and safe for animals and humans.

Novel glycopeptide antibiotic derivatives, processes for their preparation, their use as a medicine, their use to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections are provided. The present invention relates to the use of glycopeptide antibiotics and their semisynthetic derivatives to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections of subjects, more in particular infections with viruses belonging to Retroviridae, Herpes viridae, Flaviviridae and the Coronaviridae, like HIV (human immunodeficiency virus), HCV (hepatitis C virus), BVDV (bovine viral diarrhoea virus), SARS (severe acute respiratory syndrome) causing virus, FCV (feline coronavirus), HSV (herpes simplex virus), VZV (varicella zoster virus) and CMV (cytomegalovirus).

The invention relates to a kind of natural medicine of broad spectrum antibiotic. At present, the broad spectrum antibiotic medicine with high effect and safety is at shortage all round the world. The invention is intended to extract laminarinsulphate or sulphonic acid sugar ester or sulphosalts from plant chickweed or other chickweed plant with two resin adsorption methods or a water extraction and alcohol precipition method. The spectrum antibiotic in the invention is distributed under 50,000 in the formula weight formed by carbon glycosidic bond and/or oxide glycosidic bond with phenol, especially the total flavones comprising apigenin. However, the invention mainly acts as total phenolic glycoside with the formula weight under 4,000. Besides, the invention can form brownish compound with the total flavones comprising apigenin and the glycosidic ingredients without sulfur element, so as to be applied as broad spectrum antibiotic drug. Therefore, the compound in the invention can be applied to cure ADIS virus, hepatitis virus, influenza virus and parainfluenza virus comprising SARS, adenovirus, verruca acuminate virus, enterovirus, mumps virus, herpes simplex virus, herpes zoster virus and varicella. No toxic effect has been found in the application. What is more, the invention can be made into 10 sorts of formulation, disinfector and health-improving products.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses, especially HBV.

The invention provides a kit for genotyping VZV (Varicella-Zoster Viruses). The kit is characterized by comprising a nucleotide sequence shown as the Table 3 in the specification, and specific primers and specific probes corresponding to clade1-5 type VZV of chemical structures. The kit has the function of detecting various kinds of VZV DNA (Deoxyribonucleic Acid); the detection sensitivity is 10<2> copies/reaction; no cross reaction with human genome, herpes simplex viruses type I/type II, cytomegaloviruses and EB viruses exists; and the kit is applicable to the virus gene diagnosis of clinical VZV infected persons, and can also be used for the epidemiology survey of different Clade types of VZV.

The invention belongs to natural products separating and extracting technical field, particularly relating to a process for simultaneously extracting essential oil, flavone and triterpene out of wrinkled giant hyssop. The invention provides a novel separating and extracting process, which can simultaneously separate and extract essential oil, flavone and triterpene by taking wrinkled giant hyssop as raw materials; the used raw materials can be wrinkled giant hyssop as well as cablin pacholi, fresh or dried herbs as well as fresh or dried leaves, stems or other parts. When fresh wrinkled giant hyssop leaves are used as the raw materials, the essential oil thereof comprises more than 40 volatile components such as cis form - isomenthone, anti form - isomenthone piperitone, hexenoic aldehyde, delta-cadinene, cadinol, alpha-muurolene, limonene and pulegone, wherein main volatile components are the cis form - isomenthone and the anti form- isomenthone, contents of which are 34.11 percent and 15.42 percent respectively; the total flavone comprises flavonoids such as acacia substance, tilianin, linarin, agastachoside, isoagastachoside, agastachin, apigenin, apigenin-7- glucoside, 6-methoxyl group apigenin, luteolin and luteolin-7- glucoside, etc., wherein main flavone components are the agastachoside and the isoagastachoside , contents of which are 25.8 percent and 8.21 percent respectively; the triterpene materials comprises triterpene compounds such as cralaegolic acid, oleanolic acid, 3-acetyl oleanolic aldehvde, 3- acetyl oleanolic acid, alpha-amyrin, beta- amyrin, campesterol, campestanol, ursolic acid, erythrodiol, erythrodiol-3-acetic ester, wherein the main triterpene component is the cralaegolic acid , the content of which is 34.6 percent. The components have wide biological activities and a plurality of effects such as liver protection, anti-tumor, anti-HIV-1, anti-proteinase activity of HIV-1, anti-herpes zoster virus and immunity improvement, etc.

A water soluble of Penxiluowei contains the Penxiluowei or its salt, solubilizer, cosolvent and pH regulator. It can be used to prepare injection, eye drops and nose drops for treating the diseases caused by herpes simple virus, herpes zoster virus and hepatitis B virus.

The present invention relates to novel Varicella-zoster virus strain and to a chicken pox and herpes zoster virus vaccine using the same. More particularly, the present invention relates to genome DNA of VZV MAV/06 strain isolated from a Korean patient, to an open reading frame (ORF) thereof, to a protein coded by the genome DNA of VZV MAV/06 strain and the ORF thereof, and to a vaccine composition which contains the protein as an active ingredient.

The invention discloses a highly effective antiviral medicinal composition of chickweed, a preparation method and an application thereof. Presently, highly effective, safe and universal antiviral medicine is lacking all over the world. A plant, chickweed, or other stellaria plant is extracted, by two resin adsorption methods, one water-alcohol extraction and ultra-filtration, into a dark brown composition that has a molecular distribution ranging from 2,000 to 900,000 Dolton and comprises total sulfate peptidoglycan phenolic acidic components and flavonoid components; the composition is used as a safer, more highly effective universal antiviral natural medicine. Total peptides account to 15-25 percent of the chemical structures of dark brown total sulfate peptidoglycan phenolic-acidic components, and include totaling 17 amino acids by proportion: aspartic acid, glutamic acid, serine, histidine, cystine, methionine, isoleucine; the polysaccharides essentially consist of glucose, galactose and arabinose and form sulfate polysaccharides. The composition can be used for treating virus diseases, including AIDS virus, hepatitis virus, respire virus such as influenza virus including highly pathogenic bird flu virus, para influenza virus and adenovirus, and papovavirus, enterovirus, mumps virus, herpes simplex virus, herpes zoster virus, and varicella-zoster virus, and on the like, does not show toxicity, and can be prepared into more than 10 medicinal dosage forms and healthcare products, and the production process does not cause pollution to the environment.

The invention provides a varicella-zoster virus r-gE fusion protein, a recombinant varicella-zoster vaccine and a preparation method and application of the varicella-zoster virus r-gE fusion protein and the recombinant varicella-zoster vaccine. An antigen of the recombinant varicella-zoster vaccine is the varicella-zoster virus r-gE fusion protein, the recombinant varicella-zoster vaccine can be an adjuvant compatible varicella-zoster vaccine which is formed by compatibility of an r-gE fusion protein and an adjuvant, or a recombinant adenovirus vector varicella-zoster vaccine which is formed by gene recombination of the r-gE fusion protein and an adenovirus vector or an adenovirus vector containing a TLR receptor stimulant. The recombinant varicella-zoster vaccine is suitable for preventing or improving varicella-zoster and/or post-varicella-zoster neuralgia; the varicella-zoster virus r-gE fusion protein can further be used for preparing a respiratory syncytial virus and varicella-zoster combined vaccine, and the combined vaccine is formed by compatibility of the r-gE fusion protein, RSV Pre-F protein mixed liquor and the adjuvant; and the prepared combined vaccine can be used for preventing or improving respiratory syncytial virus infection diseases and varicella-zoster.

The invention discloses a folium artemisiae argyi plaster for treating herpes zoster and particularly relates to the technical field of traditional Chinese medicines. The folium artemisiae argyi plaster includes following raw materials, by weight: 50-80% of wild folium artemisiae argyi, 1-10% of borneol, 1-5% of lanolin, 1-3% of Vaseline, 1.5-3% of rhizoma corydalis, 10-15% of sesame oil, a nonwoven cloth and the like. The raw materials are mixed with an excipient to obtain a plaster-like round piece. The folium artemisiae argyi plaster is simple in preparation method, can resist herpes zoster virus, is free of any toxic and side effects, has effects of warming menstruation and stopping bleeding, dissipating cold and relieving pain, and is significant in curative effect when being pasted onto an infected site.

The invention provides a varicella-herpes zoster mRNA vaccine composition, and a preparation method and application thereof. The vaccine composition comprises a messenger ribonucleic acid (mRNA) sequence for coding varicella-herpes zoster virus glycoprotein E, a derivative sequence of the messenger ribonucleic acid (mRNA) sequence and lipid nanoparticles (LNP), and the messenger ribonucleic acid (mRNA) sequence is prepared into particles with the diameter of 20-400 nanometers through microfluidic equipment. The vaccine composition can specifically enhance humoral immune response and cellular immune response against varicella-herpes zoster glycoprotein E, can be used as a varicella vaccine which does not cause latent infection of vaccine strains, and can also be used as a herpes zoster vaccine with unlimited productivity. All the components in the vaccine composition can be widely obtained, so that the vaccine cost is effectively reduced, and the vaccine yield is increased.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to Pien Tze Huang and new application of a preparation thereof in preparing a drug for treating herpes zoster. An in-vitro experiment shows that Pien Tze Huang can dose-dependently inhibit duplication of chicken varicella-herpes zoster viruses (VZV). A clinical study finds that the combination of Pien Tzehuang and anti-virus drugs of valaciclovir and acyclovir has an obvious curative effect on alert period zoster viruses due to liver yu heat from the line, improvement of clinical symptoms of a patientcan be promoted, incrustation of herpes can be quickly promoted, new herpes can be stopped from generating, pain can be relieved, and the treatment time can also be shortened; besides, the incidenceof postherpetic neuralgia and the occurrence rate of adverse reactions occurring after treatment can also be lowered, and the clinical application has obvious advantages.

The invention belongs to the field of virus vaccines and discloses a preparation method of a herpes zoster vaccine. Through combination use of a glycoprotein E envelope outer structural domain of the herpes zoster and a glycosylation locus area of envelope glycoprotein I, the herpes zoster vaccine is established, the envelope glycoprotein I, interacting with glycoprotein E of the herpes zoster, on a herpes zoster virus envelope, of the herpes zoster virus assists the glycoprotein E envelope outer structural domain of the herpes zoster in preparation of the herpes zoster vaccine, the glycosylation modification level of a vaccine protein complex is improved, the similarity of the vaccine protein complex and a natural virus envelope is improved, and the immunocompetence of the herpes zoster vaccine is improved.

The invention provides a reagent device and a method used for detecting varicella-zoster-virus antibodies. The reagent device has a long strip shape, and has a base body comprising 8 hole positions and a handle positioned on one end of the base body. From the end proximal to the handle, the 8 hole positions are sequentially a sample hole, an auxiliary agent hole, an enzyme conjugate hole, a substrate hole, a termination liquid hole, a dilution liquid hole, a reaction hole, and a dilution hole. According to the invention, based on a principle of enzyme-linked immunoassay, varicella-zoster-virus antibody is detected by using the reagent device. The method is an independent single-person analysis and detection method. The device can be used in cooperation with a corresponding specific analysis instrument. During a detection process, detection reagents or samples are injected by using a full-automatic precise dosing device. The device and the method have the advantages of automatic operation, precise dosing, high detection result accuracy, high detection result precision, and wide application prospect.

The present invention provides a pharmaceutical composition. The pharmaceutical composition comprises i) a herpes gE protein, an active fragment of the protein, a variant of the protein, or a mixture of at least two of the herpes gE protein, the active fragment of the protein and the variant of the protein; Ii) an immunostimulatory composition, wherein the immunostimulatory composition comprises a saponin and a CpG oligodeoxynucleotide, or the immunostimulatory composition comprises an adjuvant comprising the saponin, and the CpG oligodeoxynucleotide. The invention provides application of the pharmaceutical composition in preparation of a medicine for preventing and/or treating chicken pox-herpes zoster virus infection and/or chicken pox-herpes zoster virus mediated diseases. The pharmaceutical composition provided by the invention achieves an unexpected technical effect and can mediate stronger immune response.

The invention discloses a chickenpox-zoster virus glycoprotein E gene expression vector, a recombinant yeast strain thereof and the application thereof. The vector is chickenpox as shown in SEQ ID NO:1. The complete gene sequence of herpes zoster virus glycoprotein E and the linker of pGAPZ alpha A. The expression system of the Pichia pastoris disclosed by the invention can successfully express chickenpox. The glycoprotein E of herpes zoster virus lays a foundation for the following immunogenicity detection and high expression in Pichia pastoris as well as the development of varicella zostervaccine.

A traditional Chinese medicinal preparation for treating herpes zoster is prepared through the steps of grinding raw medicines comprising, by weight, 10-50 parts of isatis root, 5-45 parts of scorpion, 10-60 parts of Corydalis tuber, 5-45 parts of borneol, 10-55 parts of Polygonum multiflorum and 20-60 parts of black sesame oil, mixing, examining, disinfecting, and packaging. The traditional Chinese medicinal preparation has heat clearing, detoxifying, vein relaxing, pain relieving, protecting and nerve restoring efficacies for the herpes zoster, is externally applied to kill herpes zoster viruses, can block the copying of herpes zoster virus DNA, and has an obvious pain relieving effect on skins and nerves. The traditional Chinese medicinal preparation can rapidly protect and restore nutrition injured nerves within a short time, and avoids the problem of neuralgia left over curing. The above medicine can instantly relieve pains after external application, has a short treatment course, is changed once every day, and enables the herpes zoster to be cured 3-5d later.